Clinical Trial Update: A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for a first-line combination of gilteritinib, venetoclax, and azacitidine in newly diagnosed acute myeloid leukemia, including FLT3-mutate…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Flt3-mutated Acute Myeloid Leukemia

Drugs mentioned

• VIDAZA (AZACITIDINE)
• Venclyxto (Venetoclax)
• Xospata (gilteritinib)

Snippet

Sponsor: Astellas Pharma Global Development, Inc. | Conditions: Acute Myeloid Leukemia (AML), FLT3-mutated Acute Myeloid Leukemia | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING